ConquerAb Inc. is a Philadelphia-based company that specializes in the development of rapid diagnostics disposable devices for the detection and mitigation of antibody responses against protein-based therapies. Their innovative technology allows for point-of-care testing of anti-biotherapeutic antibodies in less than ten minutes, using just one drop of blood, enabling risk assessment, precision medicine, and immunogenicity comparisons for biotherapeutics. With a focus on standardization and efficiency, ConquerAb Inc. aims to address the unmet need for practical and reliable diagnostics in the growing multibillion-dollar markets of vaccines and biotherapeutics.
With three granted U.S. patents and several other patent applications, trademarks, and service marks, ConquerAb Inc. is at the forefront of developing cutting-edge solutions in the field of precision medicine. Their technology not only allows for the monitoring of patient immune status before and after vaccination but also enables the utilization of patient data from different point-of-care facilities to guide rational drug development. By providing rapid and accurate results, ConquerAb Inc. is revolutionizing the way antibody responses against biotherapeutics are detected and managed, ultimately improving the efficacy and safety of therapeutic treatments.
Generated from the website